Sutro Biopharma (STRO) Accumulated Depreciation & Amortization (2017 - 2025)

Sutro Biopharma's Accumulated Depreciation & Amortization history runs 9 years deep, the most recent figure standing at $27.4 million for Q4 2025.

• In Q4 2025, Accumulated Depreciation & Amortization fell 43.75% year-over-year to $27.4 million; the TTM figure through Dec 2025 stood at $27.4 million (down 43.75% YoY), while the FY2025 annual figure was $27.4 million, down 43.75% from the prior year.
• Accumulated Depreciation & Amortization came in at $27.4 million for Q4 2025 at Sutro Biopharma, down from $48.6 million in the prior quarter.
• In the past five years, Accumulated Depreciation & Amortization ranged from a high of $48.6 million in Q4 2024 to a low of $27.4 million in Q4 2025.
• A 5-year average of $37.9 million and a median of $37.9 million in 2022 frame the typical range for Accumulated Depreciation & Amortization.
• Across the five-year window, Accumulated Depreciation & Amortization gained 15.34% in 2024 and sank 43.75% in 2025, its largest moves.
• Sutro Biopharma's Accumulated Depreciation & Amortization stood at $33.4 million in 2021, then gained by 13.4% to $37.9 million in 2022, then grew by 11.23% to $42.2 million in 2023, then gained by 15.34% to $48.6 million in 2024, then tumbled by 43.75% to $27.4 million in 2025.
• According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods registered $27.4 million, $48.6 million, and $42.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison